Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report

Abstract

An inappropriate immunologic response to an unknown antigen has been suggested to play a role in the pathogenesis of Hidradenitis suppurativa (HS). Studies have identified elevated levels of several proinflammatory cytokines, including IL-17A and TNF-α, nominating these as possible therapeutic targets.¹ Secukinumab is an Il-17A monoclonal antibody, which binds to Il-17A and inhibits the cytokine interaction with the Il-17 receptors, inhibiting the inflammatory cascade. Here we report on a case of a 47-year-old man, with Hurley Stage III lesions at the neck, axillae, breasts, genital skin and buttocks, who had experienced only temporary benefit from different medical treatments over the years. After 12 weeks of treatment with secukinumab the number of lesions reported reported by the patient within the period of the last 4 weeks was reduced from 23 to 7, pain VAS was reduced from 5 to 3 and pain/utility/handicap VAS was reduced from 7 to 4. The results may be taken to imply that IL-17 blockade could provide a possible therapeutic approach in HS.

This article is protected by copyright. All rights reserved.

http://ift.tt/2tkdoq3